COLON CELL AND COLON CANCER CELL ASSOCIATED NUCLEIC ACID MOLECULES, PROTEIN AND PEPTIDES

Abstract: This invention relates to isolated protein and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.

Description: COLON CELL AND COLON CANCER CELL ASSOCIATED NUCLEIC ACID MOLECULES, PROTEIN AND PEPTIDES CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of Serial No. 08/597,495, filed February 2, 1996, which is a continuation-in-part of U.S. patent application Serial No. 08/511,876 filed on August 4, 1995, entitled Colon Cell and Colon Cancer Cell Associated Protein and Peptides, both of which are incorporated herein by reference. FIELD OF THE INVENTION This invention is directed to human colon cell and colon cancer cell associated antigens, nucleic acid molecules, proteins and peptides. Specifically, the proteins and peptides of the invention, which are encoded by the nucleic acid molecules of the invention, are found both in and on the surface of human colon cells and human colon cancer cells, and bind to colon cancer antibodies. The protein, in a monomeric form, has a molecular weight of about 40-45 kD as determined by SDS gel electrophoresis under non-reducing conditions and about 49-55 kD when subjected to SDS-PAGE under reducing conditions. This protein, peptide fragments thereof and multimers thereof can be used to develop reagents and methods useful in the diagnosis and treatment of cancer. BACKGROUND OF THE INVENTION Colorectal carcinoma is a malignant neoplastic disease. There is a high incidence of colorectal carcinoma in the Western world, particularly in the United States. Tumors of this type often metastasize through lymphatic and vascular channels. Many patients with colorectal carcinoma eventually die from this disease. In fact, it is estimated that 62,000 persons in the United States and 8000 persons in Australia die of colorectal carcinoma annually. To date, systemic therapies and chemotherapies have been developed for the treatment of colorectal cancer. However, no therapies have exhibited sufficient anti-tumor activity to prolong the survival of colorectal carcinoma patients with metastatic disease, with any degree of reliability. As a result, a need still exists to develop methods and products for the successful treatment of colorectal carcinoma. Monoclonal antibody A33 is a murine immunoglobulin that has undergone extensive preclinical analysis and localization studies in patients (see Welt et al. , J. Clin. Oncol.. 8:1894-1906 (1990), Welt et al. , J. Clin. Oncol., 12:1561-1571 (1994) , and Welt et al . J. Clin. Oncol. 14: 1787-1797 (1996) . This antibody binds to an antigen found in and on the surface of normal colon cells and colon cancer cells. This antigen is known as the A33 antigen. In carcinomas originating from the colonic mucosa, the A33 antigen is expressed homogeneously in more than 95% of cases. The A33 antigen has not been detected in a wide range of other normal tissues studied. Its restricted expression defines this system as essentially "organ- specific" (colon, rectum and small bowel) . Immunofluorescence experiments have revealed that mAb A33 is internalized into the macropinosomes of A33 antigen- positive cells in vitro (Daghighian et al. , J. Nuc. Med. , 37: 1052-1057 (1996) . In a mouse model, mAb A33 has been found to localize to xenografts of human colon cancer in substantial amounts, and it can be identified in the cytoplasm of transplanted colon cancer cells within the first hour after administration. Rapid tumor localization and high level of antibody uptake by tumors are thought to be related to the following factors: (1) A33 antigen is not secreted, and targeting of mAb A33 to tumor cells is therefore not impeded by shed A33 antigen diffusing from tumor cells to the vascular system; (2) mAb A33 is rapidly internalized into the cell once it binds to A33 antigen on the cell membrane, thereby increasing the amount of cell associated antibody; and (3) some colon cancer cell lines express large amounts of A33 antigen, binding up to 800,000 mAb A33 molecules per cell. Due to these properties, a need exists to isolate, characterize and sequence the A33 antigen, as well as related proteins with similar characteristics. Many purification protocols typically utilize reduction steps in order to analyze proteins of interest by SDS-gel electrophoresis. In this way, proteins can be identified and monitored more easily. The inventors of the instant application found that surprisingly, by utilizing reducing conditions, they were unable to identify the target A33 protein by Western blotting. Standard techniques had to be changed so as to completely remove reducing steps in order to identify, monitor and characterize the A33 antigen of the invention. Once the antigen was isolated, studies on its behavior under reducing conditions could be carried out. Purification of the A33 antigen has been further complicated by co-migration of other proteins, including actin, to about the same position on one and two dimensional gel electrophoresis. In addition, mAb A33 binds non-specifically to actin. The inventors of the instant application identified the Fc region of the antibody as being responsible for the non-specific binding to actin. Removal of the Fc region has allowed the inventors to prevent actin binding. As actin is not a cell surface antigen on colon carcinoma cells, and is not sensitive to reduction, it became clear to the inventors that actin could not be the target for monoclonal antibody A33. The difficulty in identifying, isolating and characterizing this antigen is evidenced by the fact that although the existence of the A33 antigen has been known for more than a decade, this is the first successful purification, isolation and sequencing of the antigen. As described herein, the inventors of the instant application have identified, isolated and characterized the A33 antigen. The inventors have also isolated cDNA encoding the A33 antigen, determined the nucleotide sequence of the cDNA, and deduced the amino acid sequence for the A33 antigen. The A33 antigen, also referred to herein as the A33 protein, can be utilized to develop clinical reagents and methods useful in the prognosis, diagnosis and treatment of cancer and other diseases, in particular, cancers such as colon, rectum, gastric and small bowel mucosa cancer. SUMMARY OF THE INVENTION This invention is directed to an isolated protein which is found inside and on the surface of normal human colon cells and human colon cancer cells, as well as to peptide fragments of said protein. The protein and peptides are bound by the A33 colon cancer antibody or by polyclonal antibodies raised against regions of the protein sequence. When analyzed by SDS gel electrophoresis, the isolated glycoprotein of the invention has a molecular weight of about 40-45 kD, when non-reducing conditions are utilized and about 49-55 kilodaltons under reducing conditions. This invention further relates to nucleic acid molecules encoding said protein, and to the use of said glycoprotein, peptides and nucleic acid molecules in the diagnosis and treatment of cancer. BRIEF DESCRIPTION OF THE DRAWINGS The above brief description, as well as further objects and features of the present invention, will be more fully understood by reference to the following detailed description of the presently preferred, albeit illustrative, embodiments of the present invention when taken in conjunction with the accompanying drawings wherein: Figure 1 represents cytofluorographic analysis of the LIM1215 and Hep-2 cells with A33 monoclonal antibody; Figure 2 shows that A33 antigen is detectable by Western blot after SDS gel electrophoresis using non- reducing conditions, but not detectable after SDS gel electrophoresis using reducing conditions. "-B-ME" indicates non-reducing conditions and "+-BME" refers to reducing conditions; Figure 3 shows immunoprecipitation of cell lysates with or without mAb A33; Figure 4 shows immunoprecipitation of cell lysates which were or were not incubated with tunicamycin; Figure 5 is comprised of Figures 5A and 5B, and represents Western blot analysis of A33 antigen extracted from LIM1215 cells under non-reducing conditions; Figure 6 shows biosensor analysis of the interaction between actin and either A33 IgG or the A33 F(ab) ' 2 fragment; Figure 7 is a flow chart depicting the chromatographic purification protocol used to purify A33 antigen; Figure 8 is comprised of Figures 8A and 8B and shows Western blot analysis of Triton X-100 and Triton X-114 extracts of LIM1215 colonic cells, respectively; Figure 9 shows anion-exchange HPLC of the A33 antigen; Figure 10 shows size-exclusion HPLC of the A33 antigen; Figure 11 is comprised of Figures 11A and 11B. Figure 11A shows micropreparative RP-HPLC purification of Superose 12 active fractions. Figure 11B shows biosensor analysis of the A33 antigen activity in the HPLC fraction; Figure 12 represents amino acid sequences of peptide fragments in the A33 antigen; Figure 13 is a flow chart which shows a protocol used for affinity purification of A33 antigen; Figure 14 represents Western blot analysis of sera obtained from mice and rabbits immunized with chemically synthesized peptide SVETPQDVLRASQGKSVTLP (amino acids 2-21 of SEQ ID NO: 1) conjugated to keyhole limpet hemocyanin (KLH) ; Figure 15 represents Western blot analysis of the A33 antigen under non-reduced (panel 1) and reduced (panel 2) conditions using an anti-peptide IgG raised against the N- terminus of the A33 antigen; Figure 16 is comprised of Figures 16A and 16B. Figure 16A, and its continuation Figure 16B, represent the 2.6kb cDNA which encodes the A33 antigen; Figure 17 is a comparison of deduced amino acid sequences for human and murine A33; Figure 18 shows that mAb A33 precipitated labelled A33 antigen, following labelling with palmitate; Figure 19 depicts the abolition of staining when hydroxylamine was used. DETAILED DESCRIPTION OF THE INVENTION Example 1 Several colon cancer cultured cell lines, listed in Table 1, were obtained. The LIM1215 cell line was obtained from Ludwig Institute for Cancer Research, Melbourne, Australia. Cell lines SK-CO-17, SK-CO-19, SK-CO-10, SK-CO- 11 and SK-CO-15 were obtained from Ludwig Institute for Cancer Research, New York, and Memorial Sloan Kettering Institute, New York. All other cell lines were obtained from the American Type Culture Collection, Rockville, Maryland. Using the protocol described by Pfreundschuh et al., Proc. Natl. Acad. Sci. USA, 75:5122-5126 (1978) , rosetting assays were performed on each of these cell lines using monoclonal antibody A33 (mAb A33) , secreted by a hybridoma cell line which was deposited under the Budapest Treaty with the American Type Culture Collection, Rockville, Maryland and catalogued as ATCC No. HB 8779. mAb A33 has an isotype of IgG2a and, as described herein, binds to an antigen denoted A33 which is present in and on the surface of human colon carcinomas. Several of the colon carcinoma cell lines were found to be A33-positive, as determined by rosetting assays, immunoassays and immunohistochemistry (see Table 1 which follows) . Table 1 REACTIVITY OF mAb A33 WITH HUMAN COLON CANCER CELL LINES Cell Line Rosetting A. Western Blot Immune precip. Titer A33 Positive Colon Lines LIM 1215 2 13 +++ ++ L0V0 2 12 + LS 174T 2 12 LS 180 2 n ++ NCI -H508 2 12 + + + + + SK-CO- 17 2 9 + SK- CO- 19 2 13 SNC- 2B 2 12 SW403 2 13 + SW1222 2 12 + + + ++ COLO 205 + + °° ASPC- 1 (pancreatic ) 2 13 ++ + + A33 Negative Colon Lines DLD1 HCT15 HT29 SK-CO-10 SK-CO-11 SK-CO-15 SW480 SW620 - - SW837 - SW1116 - - SW1417 - Example 2 The LIM1215 colonic cell line, which was positive in the rosetting assays of Example 1, was grown in RPMI medium containing 10% fetal calf serum. Confluent cells (10 6 /cm 2 ) were passaged using Trypsin-Versene solution. Cells were seeded 1/10 into tissue culture dishes containing 25 ml RPMI 1640 supplemented with 10% fetal calf serum, 1 μg/ml hydrocortisone, 0.025 U/ml insulin and 10.82 μg/ml a- thioglycerol. The dishes were incubated at 37°C in an atmosphere of 5% C0 2 for 5 days. After removing the media, cells were washed with PBS before being removed from the surface using a cell scraper. Cells were washed in PBS and resuspended at 10 9 cells/ml. A33 antigen expression on the surface of the LIM1215 colonic carcinoma cell line was then analyzed by flow cytometry following standard techniques. The Hep-2 epidermoid carcinoma cell line (Boring et al. , Cancer J. Clin. , Vol. 44, pp. 7-26 (1994)) was used as a negative control. The cells were washed and resuspended at 5 x 10 6 cells/ml in 500 μl of PBS containing 5 mM EDTA and 5% fetal calf serum. The cells were incubated with 5 μg A33 mAb for 30 minutes at 4°C. After washing with buffer, the cell/antibody complexes were incubated with fluorescein- conjugated anti-murine IgG (1/50 dilution) . A negative control was performed by staining the cells with an isotopically matched non-related antibody (5 μg) followed by fluorescein-conjugated anti-murine IgG alone. Flow cytometry was performed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, U.S.A.) . Figure 1 shows cytofluorographic analysis of LIM1215 and Hep-2 cells with A33 monoclonal antibody. The entire population of LIM1215 cells exhibited a strong homogeneous fluorescence (panel B) when incubated with A33 mAb, compared with the fluorescence obtained with the control antibody (panel A) . The profiles shown in the panels obtained with the Hep-2 cells (C and D) were overlapping, indicating no detectable A33 mAb binding to these cells. The X axis shows the fluorescence intensity (log scale) and the Y axis shows the cell number. Example 3 Cell lines which were A33-positive in rosetting assays (Table 1) were lysed using 0.3% Triton X-100 in PBS, pH 7.4. Other detergents known to those skilled in the art can also be used to lyse A33-positive cells. The cell lysates of nine A33-positive cell lines and, in addition, five A33-negative cell lines (controls) were probed for A33 antigen expression by Western blot analysis using non- reducing conditions. A molecule with a molecular weight of about 43 kD was detected by Western blotting with mAb A33 in lysates from colon cancer cells which were A33-positive by rosetting assay. This molecule was not detected in lysates obtained from cell lines which tested negative for A33 in rosetting assays, or by antibodies other than mAb A33, including anti-actin mAb. The A33 antigen was detectable by Western blot analysis only after SDS gel electrophoresis using non-reducing conditions. The A33 antigen was not detectable using reducing conditions. The Western blot shows in Figure 2 utilized A33 antigen obtained by affinity purification from SW1222 cells. The upper band (Figure 2) indicates multimeric form of the A33 protein. Example 4 A33 antigen was immunoprecipitated from colon carcinoma cell lysates. In order to do this, colon cancer cells were labeled with 3 H-GlcNAc or 35 S using standard techniques known to those skilled in the art . Cell lysates which were A33 positive by rosetting assays, and which exhibited a band of about 43 kD by SDS gel electrophoresis under non-reducing conditions, were immunoprecipitated with monoclonal antibody A33. Figure 3 shows that a molecule was immunoprecipitated from A33-positive lysates which has a molecular weight of about 43 kD. This band was not precipitated by lysates which were A33-negative in rosetting assays. In addition, this band was not precipitated by antibodies other than mAb A33 ("no. l°Ab" indicates that mAb A33 was not used) . Since 3 H-GlcNAc is a carbohydrate, which is incorporated into the glycosylation side of glycoproteins, these results suggest that the A33 antigen contained in the band is a glycoprotein. Additional evidence in support of this is provided in examples which follow. Example 5 35 S-labeled SW1222 cells were incubated with 5 μg/ml tunicamycin for 18 hours. Tunicamycin is known to block N- glycosylation of glycoproteins. These cells, as well as cells which were not incubated with tunicamycin, were lysed and subjected to immunoprecipitation with A33 antibody, FB- 5 antibody (control) or no antibody (control) . Figure 4 shows the immunoprecipitation results. Of the cells which were not incubated with tunicamycin, immunoprecipitation with A33 antibody showed a band at about 43 kD. Immunoprecipitation with antibody FB-5, which was an isotype control or no antibody, showed no such 43kD band. Of the cells incubated with tunicamycin, immunoprecipitation with A33 antibody showed a band at 43kD, as well as three other bands of lower molecular weight. These lower molecular weight bands indicate the presence of A33 antigen with a different degree of glycosylation due to the presence of tunicamycin. This provides further evidence that the A33 antigen is a glycoprotein, and contains N-linked oligosaccharides . Example 6 A33 antigen was identified using 2-dimensional gel electrophoresis under non-reducing conditions. First, the LIM1215 colonic cell line was grown in RPMI medium containing 10% fetal calf serum. Confluent cells (10 6 /cm 2 ) were detached from the plastic dish using Trypsin-Versene solution. Cells were seeded 1/10 into tissue culture dishes (150 x 20 mm) containing 25 ml RPMI 1640 supplemented with 10% fetal calf serum, 1 μg/ml hydrocortisone, 0.024 U/ml insulin and 10.82 μg/ml a- thioglycerol, as described above. Dishes were incubated at 37°C in an atmosphere of 5% C0 2 for 5 days. After removing the media, cells were washed with PBS before being removed from the surface using a cell scraper. Cells were washed in PBS and resuspended at 10 9 cells/ml. Next, A33 antigen was extracted from 3 x 10 8 LIM1215 cells using 0.3% Triton X-100 in 10 mM Tris-HCl buffer (pH 7.4) . The extract was diluted 1:1 with sample buffer comprised of arginine/lysine buffer, pH 10, containing 30% glycerol, and electrophoresed on small (8 x 8 cm) Novex 2- dimensional gel electrophoresis gels under non-reducing conditions. The proteins were separated in the first dimension by isoelectric focusing at a pH of 3.5-8.5, and in the second dimension by SDS-PAGE (10% acrylamide gels) . The A33 antigen was localized in the gel by staining with Coomassie Blue R-250, along with immunoblot analysis using mAb A33 (Figure 5B) . For comparison, the staining pattern observed using an anti-actin mAb (Figure 5A) is shown. Actin is used for comparison because it has similar migration characteristic to the A33 antigen. Example 7 Biosensor analysis was performed on the LIM1215 cell extracts and chromatographic fractions. The extracts and fractions were monitored using an instrumental optical biosensor (BIAcore™, Pharmacia Biosensor, Uppsala, Sweden) , with a F(ab) ' 2 fragment of A33 humanized monoclonal antibody immobilized onto the biosensor surface. To prepare the F(ab) ' 2 fragment, A33 antibodies were purified (King et al . ; Br. J. Cancer, Vol. 72, pp. 1364- 1372 (1995)) . F(ab) ' 2 fragments were generated by pepsin (1% w/w) digestion of 10 mg A33 mAb in 0.1 M sodium acetate (pH 3.5) . These were then purified by size exclusion chromatography on a Sephacryl S-200 (2.8 x 60 cm) column (Pharmacia Biotech) equilibrated with 50 mM sodium phosphate (pH 7.4) containing 0.15 mM NaCl. The elution was performed at a flow rate of 0.5 ml/min. The detection of the antigen binding to the F(ab) ' 2 fragment is based on the phenomenon of surface plasmon resonance, a technique which measures small changes in refractive index at, or near to, the gold sensor surface. Prior to the biosensor assay, cell extracts and chromatographic fractions were diluted to 100 μl final volume in BIAcore™ buffer (HBS) : 10 mM Hepes (pH 7.4) containing 3.4 mM EDTA, 0.15 mM NaCl and 0.005% Tween 20. Samples (30 μl) were injected over the sensor surface at a flow rate of 5 μl/min. Following completion of the injection phase, dissociation was monitored in BIAcore™ buffer at the same flow rate for 360 seconds. Residual bound antigen was eluted and the surface regenerated between injections using 40 μl of 10 mM NaOH. This treatment did not denature the protein immobilized onto the sensor surface as shown by equivalent signals on reinjection of a sample containing the A33 antigen. Figure 6 shows biosensor analysis of the interaction between actin and either the complete A33 antibody or the A33 F(ab)' 2 fragment. A preparation of rabbit muscle actin (0.3 μg) was injected at a flow rate of 5 μl/min over a sensor surface which had been immobilized with either whole A33 (upper trace) or A33 F(ab) ' 2 fragment (lower trace) . Protein/protein interactions were monitored by surface plasmon resonance. At the end of the injection pulse, a signal of 247 RU was observed due to actin binding to A33 IgG, while the signal corresponding to actin binding to A33 F(ab) ' 2 was only 4 RU (as indicated by arrows) . Example 8 A33 antigen was purified from LIM1215 cells for sequence analysis. Figure 7 is a flow chart which depicts the chromatographic purification protocol used to purify A33 antigen. To extract A33 antigen, LIM1215 colonic cells (2 x 10 9 cells) were harvested, washed in phosphate-buffered saline (PBS) and solubilized (10 8 cells/ml) for 30 minutes at 4°C with either 0.3% (v/v) Triton X-100 or 1% (v/v) Triton X-114 in 15 mM Tris-HCl (pH 7.4) containing 1 mM PMSF, ImM pepstatin, 0.1 mM leupeptin and 0.01 U/ml aprotinin. The resulting extracts were centrifuged twice at 4°C for 20 minutes at 14,000g. The Triton-XlOO supernatant was taken directly for Green-Sepharose HE-4BD chromatography. The Triton X-114 extracted supernatant was layered over 6% sucrose in 15 mM Tris-HCl (pH 7.4) with 0.06% (v/v) Triton X-114, containing the protease inhibitors listed above. The tubes containing the Triton X-114 extracts and the sucrose were incubated at 37°C for 30 minutes and then centrifuged at 25°C for 15 minutes at 5,000g. The detergent phase was collected for chromatographic purification. In order to perform Green-Sepharose chromatography, Triton-XlOO extracts or the Triton X-114 detergent phase were diluted to a final concentration of 0.1% Triton and loaded at 4°C onto a Green-Sepharose HE-4BD column (100 x 10 mm ID) connected to a Fast Protein Liquid Chromatography system (FPLC, Pharmacia Biotech, Uppsala, Sweden) . The column was equilibrated with 10 mM Tris-HCl (pH 7.4) containing 0.1% CHAPS (w/v) . Bound proteins, including actin, were eluted stepwise with 1M NaCl. The breakthrough contained the A33 antigen, and was collected for anion- exchange HPLC, as described below. Example 9 Western blot analysis was performed throughout purification to confirm the presence of A33 antigen. Electrophoresis and Western blot analysis were performed on precast Phastgels using a Phastsystem separation and control unit (Pharmacia Biotech) . Cell extracts and chromatographic fractions were electrophoresed under non- reducing conditions as described by Reid et al, Electrophoresis, Vol. 16, pp. 1120-1130 (1995) , on 8-25% SDS-PAGE Phastgels or 8-25% native Phastgels and transferred onto PVDF membranes and incubated with A33 monoclonal antibody. RP-HPLC purified A33 antigen was also analyzed by Western blot under non-reducing and reducing conditions using polyclonal anti-N-terminal peptide antibodies (described herein) . IgG binding was probed with horseradish peroxidase-labelled goat anti-mouse IgG, goat anti-human IgG or goat anti-rabbit IgG and detected by enhanced chemiluminescence (ECL) . Figure 8 shows Western blot analysis of the Triton X-100 and Triton X-114 extracts of LIM1215 colonic cells. Panel A shows the following: Lane 1: LIM1215 cells solubilized in 0.3% Triton X-100. Lane 2: Green-Sepharose breakthrough containing the 43K A33 antigen. Lane 3: Green-Sepharose binding proteins eluted with 1M NaCl containing a 41kD molecular weight band. Lane 4: Rabbit muscle Actin (1 μg) . Panel B shows the following: Lane 1: LIM1215 cells solubilized in 1% Triton X-114. Lane 2: Triton X-114 aqueous phase. Lane 3: Triton X-114 detergent phase. Lane 4: Green-Sepharose breakthrough. Lane 5: Green-Sepharose binding proteins eluted with 1M NaCl . Example 10 Following Green-Sepharose chromatography (described above) , anion-exchange HPLC was performed. The Green- Sepharose breakthrough was injected at 4°C onto a Mono Q HR 10/10 column previously equilibrated in 10 mM Tris-HCl (pH 7.4) containing 0.1% (w/v) CHAPS. The proteins were eluted from the column using a linear 0-1M NaCl gradient generated over 90 minutes at a flow rate of 1 ml/min. Fractions (1 ml) were collected automatically using a fraction collector (FRAC 100, Pharmacia Biotech) . Proteins were detected by absorbance at 280 nm. The A33 antigen was detected using both Western blotting under non-reducing conditions and biosensor analysis. Figure 9 shows anion-exchange HPLC of the A33 antigen. The proteins contained in the Green-Sepharose breakthrough fraction which were loaded onto the Mono Q HR 10/10 anion- exchange column and eluted at a flow rate of 1 ml/min with a linear gradient from 0-1 M NaCl are indicated ( ) . One ml fractions were collected and aliquots (20 μl) of each of the fractions were taken for biosensor assay. The approximately 43 kD antigen was detected in the labelled fractions by Western blot analysis under non-reducing conditions (inset, Figure 9) as described herein. Example 11 Next, size-exclusion HPLC was performed. The active fractions eluted from the Mono Q column (10 ml) were concentrated 10 fold using a Speed Vac concentrator (Savant Instruments Inc., NY, U.S.A.) , dialyzed against PBS containing 0.05% CHAPS (w/v) and loaded at 4°C onto a Superose 12 HR 10/30 column. Proteins were eluted with PBS containing 0.05% (w/v) CHAPS at a flow rate of 500 μl/min. Fractions (0.5 ml) were collected. Proteins were detected at 280 nm and the A33 antigen was monitored using both Western blotting and biosensor analysis as described above. Figure 10 shows size-exclusion HPLC of the A33 antigen. The elution positions of protein calibration standards (BSA dimer, BSA and trypsin inhibitor) are indicated above the chromatographic trace. The A33 antigen was also detected by Western blot analysis under non- reducing conditions (inset A) in the fractions indicated. Immunoblot analysis of a pool of the Superose 12 activity (fractions 2-5) using an 8-25% native gel revealed that the A33 antigen migrated under native conditions (no SDS) with a relative molecular mass of 180 kD (inset B, Figure 10) . Example 12 Reversed-phase HPLC chromatography was then performed. Superose 12 active fractions (2.5 ml) were loaded at a flow rate of 1 ml/min, by multiple 1 ml injections, onto a Brownlee Aquapore RP 300 micropreparative RP-HPLC column (30 x 2.1 mm ID) equilibrated with the primary solvent, 0.15% (v/v) trifluoroacetic acid (TFA) in water. The proteins were eluted with a linear 60 minute gradient to 60% aqueous n-propanol / 0.125% (v/v) TFA at a flow rate of 100 μl/min. The column temperature was 45°C. Protein detection was performed at 215 nm. The A33 antigen was detected using both Western blotting and biosensor analysis. The peak containing the A33 antigen was repurified and further concentrated using a Brownlee Aquapore RP 300 micropreparative RP-HPLC column (100 x 1 mm ID) prior to N-terminal sequence analysis, using the gradient conditions described above at a flow rate of 50 μl/min. Eluent fractions were recovered manually. Figure 11 shows micropreparative RP-HPLC purification of Superose 12 active fractions. Panel A, main frame, shows the elution profile of the fractions from micropreparative RP-HPLC as analyzed by absorbance at 215 nm and by biosensor. Panel A, inset A, shows aliquots (2 μl) of- each fraction, analyzed by SDS-PAGE (8-25% gel, silver stained) , and Panel A, inset B, shows a Western blot under non- reducing conditions. Panel B shows biosensor analysis of individual fractions from micropreparative RP-PHLC. Aliquots (20 μl) of each fraction were concentrated using a Speed Vac concentrator and redissolved in 100 μl of BIAcore™ buffer. 30 μl aliquots were analyzed using the biosensor. Activity was found in the fractions eluting between 46 and 48 minutes. Example 13 As discussed above, the A33 antigen-containing reversed-phase HPLC fractions were pooled for amino acid sequence analysis. N-terminal amino acid sequence analysis of purified A33 antigen/protein was performed on a Hewlett- Packard model G1005A protein sensor operated with the routine 3.0 sequencer program described by Reid et al. , Electrophoresis, Vol. 16, pp. 1120-1130 (1995) . The following N-terminus sequence of 30 amino acids was obtained: (SEQ ID NO: 1) XSVETPQDVLRASQGKSVTLPXTYHTSXXXREGLIQWD. A search of all of the available protein, DNA and expressed sequence tag databases did not reveal any significant amino acid sequence identity of the A33 N-terminus with known proteins. In addition, A33 antigen-containing reversed phase HPLC fractions were subjected to tryptic digestion as described by Simpson et al. , Eur. J. Biochem. , Vol. 183, pp. 715-722 (1989) . Peptide fragments Tl and T2 were obtained. The amino acid sequences for these peptide fragments are shown in Figure 12. Example 14 A33 antigen-containing fractions were obtained from SW1222 cells utilizing the protocol shown in Figure 13. To perform affinity chromatography, the A33 affinity column was prepared according to the protocol described by Schneider et al. , J. Biol. Chem. Vol. 257, pp. 10766-10769 (1982) . A33 monoclonal antibody was diluted to 1 mg/ml in 0.1 M borate, pH 8.2, and incubated overnight at 4°C with 1.5 ml Protein A-Sepharose. After washing with 0.1 M borate, pH 9.2, the Protein-A-monoclonal antibody complex was incubated for 1 hour at room temperature with 20 mM dimethylpimelimidate in 0.1 M borate, pH 9.2. Non- covalently bound antibody was removed with 50 mM glycine, pH 2.5. The remaining active dimethylpimelimidate groups were deactivated by washing and incubating the beads with 0.1 M ethanolamine pH 8.0. The reversed-phase HPLC fractions were pooled for amino acid sequence analysis. Sequence analysis was performed as described in Example 13. The following A33 N- terminus sequence was obtained: (SEQ ID NO: 4) ISVETPQDVLRASQGKSVTLPXTYHTSTSSREGLIQWDKL A sequence search did not reveal any significant amino acid sequence identity with known proteins. This N-terminus sequence was utilized to obtain the cDNA sequence which encodes A33 antigen (described below) . In addition, A33 antigen-containing reversed phase HPLC fractions were subjected to Asp-N endoproteinase digestion as described by Simpson et al . , Eur. J. Biochem., Vol. 183, pp. 715-722 (1989) . Peptide fragments Dl, D2, D3 and D4 were obtained. These peptides were purified by micropreparative RP-HPLC. The amino acid sequences for these peptide fragments are shown in Figure 12. It was determined that there was a lack of an amino acid in cycle 3 of the Edman degradation of peptide D4. Asp 112 was flanked by Thr at position 114. As this is a classical N- glycosylation motif, evidence was provided that A33 protein is N-glycosylated. Fractions were also subjected to pepsin digestion, as described by Sarkar et al, Proc . Nat ' 1 Acad. Sci . U.S.A., Vol. 88, pp. 234-238 (1991) . Peptide fragment PI was obtained. The amino acid sequence for peptide fragment PI is shown in Figure 12. RP-HPLC fragments were subjected to Thermolysin/pepsin/Asp-N digestion. Thermolysin digestion was performed as described by Sarkar, supra. Peptide fragments Pel and Pc2 were obtained. The amino acid sequences for peptide fragments Pel and Pc2 are shown in Figure 12. Example 15 Immunization studies were performed utilizing an immunogen derived from the amino acid sequence of the N- terminus of A33 antigen. A chemically synthesized peptide, SVETPQDVLRASQGKSVTLP (amino acids 2-21 of SEQ ID NO: 1) was conjugated to KLH and injected, with adjuvant, into two mice and into two rabbits. Rabbits were immunized four times at three week intervals. In the first immunization, complete Freund's adjuvant (CFA) was used. In subsequent rabbit immunizations, incomplete Freund's adjuvant (IFA) was used. Mice were immunized four times at two week intervals, using standard adjuvant. Sera were obtained from the rabbits and from the mice. The sera were subjected to Western blot analysis. It was found that both the rabbits and mice developed IgG antibodies which reacted with the peptide, and also with the 43 kD band (the same 43 kD band was recognized by mAb A33) in using cell line SW1222 (Figure 14) . IgG was purified from rabbit immune sera by Proteih-A affinity chromatography. Purified IgG was characterized by SDS-PAGE and Western blot analysis for reactivity with LIM1215 cell lysates and purified A33 antigen. The IgG was found to react strongly with the 20 amino acid peptide discussed supra, and with the approximately 43 kD protein which was recognized by mAb A33 under non-reducing conditions. In addition, rabbit IgG anti-serum reacted strongly with whole A33 antigen in reduced form (Figure 15) . HPLC purified A33 antigen from LIM1215 (0.1 μg) was electrophoresed on an 8- 25% SDS-PAGE Phastgel under non-reducing (Figure 15, lane 1) and reducing (Figure 15, lane 2) conditions and analyzed by Western blot using an anti-peptide IgG raised against residues 2-21 of SEQ ID NO: 1, as described above. The A33 antigen N-terminus sequence, and fragments thereof, can be used to develop A33 antigen-specific antibodies. These antibodies will recognize and bind to A33 antigen or fragments thereof, in either reduced or non-reduced form. Example 16 The amino acid sequence of the A33 N-terminus of A33 protein was used to clone A33 protein cDNA. Poly (A) + RNA (80 μg) was prepared in-house from confluent LIM1215 cells by two rounds of enrichment on columns of oligo (dT) cellulose using standard procedures. A LIM1215 cDNA library was custom- synthesized in the λZAPII expression vector by Clontech (Palo Alto, California, U.S.A.) using oligo (dT) and random hexamer primers to prime first strand DNA synthesis (standard procedures) , using this mRNA. Successful screening of the library was achieved with a DNA probe generated from the LIM1215 cDNA library using the polymerase chain reaction (PCR) . Six 17mer antisense oligonucleotides (R9-R14) , each with only 8 -fold degeneracy, were designed to correspond to amino acid residues 34-39 of the A33 antigen N-terminal sequence (L I Q W D K (amino acids 34-39 of SEQ ID NO: 4) ) as follows : Primer #1477 (R9) 5' A(R) (Y) TT (R) TCCCACTGAAT (SEQ ID NO: 12) Primer #1478 (R10) 5' A(R) (Y) TT (R) CCCATTGAAT (SEQ ID NO: 13) Primer #1479 (Rll) 5' A(R) (Y) TT (R) TCCCACTGGAT (SEQ ID NO 14) Primer #1480 (R12) 5' A(R) (Y) TT (R) TCCCATTGGAT (SEQ ID NO 15) Primer #5915 (R13) 5' A(R) (Y) TT (R) CCCACTGTAT (SEQ ID NO 16) Primer #5916 (R14) 5' A(R) (Y) TT (R) TCCCATTGTAT (SEQ ID NO 17) These were paired with sense primers designed to hybridize to sequences present in the backbone of the λZAPII vector and were used in PCR reactions with the amplified LIM1215 cDNA library as the source of A33 antigen template. The successful reaction occurred with primers described below. For PCR reaction, the template used was amplified LIM1215 cDNA library in λZAPII vector. The primers used were as follows: KS primer 5'CGAGGTCGACGGTATCG (SEQ ID NO: 18) (17mer) (hybridizes to a sequence in multicloning site of λZAPII vector) ; and RIO primer (described above) . The reaction conditions were as follows: cDNA library (10" pfu/ml) 1 μl 10 x T'aq™ buffer 2.5 mM NTPs 15 mM MgCl 2 KS (50 pmoles/μl) RIO (50 pmoles/μl) Water Taq polymerase (added last in Hot 50.0 μl Start) The touchdown program used in the PCR was as follows: Three products were generated, and were 1.4 kb, 0.5 kb, and 0.3 kb long. The 1.4 kb product (designated RlO/l) and the 0.5 kb product (designated R10/2) were separated on a 3% agarose gel and purified using the Bresa-clean™ nucleic acid purification kit (Bresatec, Adelaide, S. Australia) . These purified products were used as templates in further PCR reactions in order to generate a greater yield of product . PCR reactions were conducted exactly as described supra, except that 1 μl of purified PCR product (either RlO/l or R10/2) was used as DNA template instead of 1 μl of the LIM1215 cDNA library. The RlO/l PCR reaction produced two bands: Upper band Size 1.4 kb (very faint) Lower band Size 0.3 kb (strong) designated 10/1 300bp The R10/2 PCR reaction produced two bands: Upper band Size 0.5 kb (strong) Lower band Size 0.3 kb (strong) designated 10/2 The 0.3 kb fragments (10/1 300bp and 10/2) were gel- purified as described above. Nucleotide sequencing of both fragments was conducted and the reverse complement of each sequence was found to encode a portion of the A33 N- terminal protein sequence. The following precise primers to the A33 antigen cDNA sequence were then synthesized in order to amplify a precise 189bp PCR product for use as a probe to screen the LIM1215 cDNA library. Primer #1747 (A33 sense primer 1) 5' CCTGTCTGGAGGCTGCCAGT (20mer) (SEQ ID NO: 19) Primer #1748 (A33 antisense primer 1) 5'AGGTGCAGGGCAGGGTGACA (20mer) (SEQ ID NO: 20) The above primers were used in a standard PCR reaction as follows, and generated a product of the predicted size (189 bp) . Standard PCR Reaction Conditions 10/l-300bp product 10 x T'aq buffer 2.5 mM NTPs 15 mM MgCl 2 Primer #1747 (50 pmoles/μl) Primer #1748 (50 pmoles/μl) Water Taq polymerase Standard PCR program as follows: 1 95° C x 5 min 2 95°C x 1 min 3 55°C x 1 min 4 72°C x 1 min 5 Go to (2) thirty times 6 72°C x 5 min 7 4°C hold The 189 bp product was separated on a 3% agarose gel and purified using the Bresa-clean™ kit. It was then radio-labelled with [α: 32 P]ATP and [α 32 P] CTP to a specific activity of >10 7 dpm/μg DNA using well known random primer reaction and Klenow polymerase procedures and used to screen 800,000 clones of the LIM1215 cDNA library (standard procedures) . After three rounds of screening thirteen purified A33 antigen cDNA clones were obtained, the longest of which was approximately 2.8 kb. See infra. The labelled PCR probe was also used in Northern analysis and produced a strong hybridizing signal with a single species of mRNA of size approximately 2.8 kb in total RNA and poly (A) + enriched RNA from LIM1215 cells, suggesting that the 2.8 kb clone was likely to be close to full-length. Several clones were sequenced and all were found to encode the A33 antigen N-terminal protein sequence. The complete nucleotide sequence of a 2.6 kb clone (clone 11) is depicted in Figure 16. When one 2.6 kb cDNA clone was radiolabelled as described above (i.e., using [o; 32 P]ATP and | 32 P] CTP in the random primers reaction with Klenow polymerase) and used in Northern analysis, a strong signal of size approximately 2.8 kb was obtained with total RNA prepared from A33 antigen positive cell lines (LIM1215, LIM1899 and LIM1863) and normal human colonic epithelial tissue, but not with total RNA form A33 antigen negative cell lines (LIM2099, LIM2405, LIM2537) . The 319 amino acid translation protein product (A33 antigen) was deduced from nucleotide sequence of several 2.6 kb clones. It was predicted that protein translation is initiated at the second ATG from the 5' end in the cDNA sequence. This was deduced by reference to the Kozak consensus sequence (GCCC(R) CCATGG (SEQ ID NO: 21)) for initiation of translation. The deduced full length translation protein product comprises 319 amino acids, and has the following amino acid sequence (SEQ ID NO: 22) Met Val Gly Lys Met Trp Pro Val Leu Trp T r Leu Cys Ala Val Arg 5 10 15 Val Thr Val Asp Ala lie Ser Val Glu Thr Pro Gin Asp Val Leu Arg 20 25 30 Ala Ser Gin Gly Lys Ser Val Thr Leu Pro Cys Thr Tyr His Thr Ser 35 40 45 Thr Ser Ser Arg Glu Gly Leu lie Gin Trp Asp Lys Leu Leu Leu Thr 50 55 60 His Thr Glu Arg Val Val lie Trp Pro Phe Ser Asn Lys Asn Tyr lie 65 70 75 80 His Gly Glu Leu Tyr Lys Asn Arg Val Ser lie Ser Asn Asn Ala Glu 85 90 95 Gin Ser Asp Ala Ser lie Thr lie Asp Gin Leu Thr Met Ala Asp Asn 100 105 110 Gly Thr Tyr Glu Cys Ser Val Ser Leu Met Ser Asp Leu Glu Gly Asn 115 120 125 Thr Lys Ser Arg Val Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro 130 135 140 Glu Cys Gly lie Glu Gly Glu Thr He He Gly Asn Asn He Gin Leu 145 150 155 160 Thr Cys Gin Ser Lys Glu Gly Ser Pro Thr Pro Gin Tyr Ser Trp Lys 165 170 175 Arg Tyr Asn He Leu Asn Gin Glu Gin Pro Leu Ala Gin Pro Ala Ser 180 185 190 Gly Gin Pro Val Ser Leu Lys Asn He Ser Thr Asp Thr Ser Gly Tyr 195 200 205 Try He Cys Thr Ser Ser Asn Glu Glu Gly Thr Gin Phe Cys Asn He 210 215 220 Thr Val Ala Val Arg Ser Pro Ser Met Asn Val Ala Leu Tyr Val Gly 225 230 235 240 He Ala Val Gly Val Val Ala Ala Leu He He He Gly He He He 245 250 255 Tyr Cys Cys Cys Cys Arg Gly Lys Asp Asp Asn Thr Glu Asp Lys Glu 260 265 270 Asp Ala Arg Pro Asn Arg Glu Ala Tyr Glu Glu Pro Pro Glu Gin Leu 275 280 285 Arg Glu Leu Ser Arg Glu Arg Glu Glu Glu Asp Asp Tyr Arg Gin Glu 290 295 300 Glu Gin Arg Ser Thr Gly Arg Glu Ser Pro Asp His Leu Asp Gin 305 310 315 It is proposed that the protein contains a 21 amino acid hydrophobic leader sequence which is cleaved to produce a 298 amino acid mature protein with the known N- terminal corrresponding to amino acids 22 -319 of SEQ ID NO : 22 , i . e . : He Ser Val Glu Thr Pro Gin Asp Val Leu Arg Ala Ser Gin Gly Lys 5 10 15 Ser Val Thr Leu Pro Cys Thr Tyr His Thr Ser Thr Ser Ser Arg Glu 20 25 30 Gly Leu He Gin Trp Asp Lys Leu Leu Leu Thr His Thr Glu Arg Val 35 40 45 Val He Trp Pro Phe Ser Asn Lys Asn Tyr He His Gly Glu Leu Tyr 50 55 60 Lys Asn Arg Val Ser He Ser Asn Asn Ala Glu Gin Ser Asp Ala Ser 65 70 75 80 He Thr He Asp Gin Leu Thr Met Ala Asp Asn Gly Thr Tyr Glu Cys 85 90 95 Ser Val Ser Leu Met Ser Asp Leu Glu Gly Asn Thr Lys Ser Arg Val 100 105 110 Arg Leu Leu Val Leu Val Pro Pro Ser Lys Pro Glu Cys Gly He Glu 115 120 125 Gly Glu Thr He He Gly Asn Asn He Gin Leu Thr Cys Gin Ser Lys 130 135 140 Glu Gly Ser Pro Thr Pro Gin Tyr Ser Trp Lys Arg Tyr Asn He Leu 145 150 155 160 Asn Gin Glu Gin Pro Leu Ala Gin Pro Ala Ser Gly Gin Pro Val Ser 165 170 175 Leu Lys Asn He Ser Thr Asp Thr Ser Gly Tyr Tyr He Cys Thr Ser 180 185 190 Ser Asn Glu Glu Gly Thr Gin Phe Cys Asn He Thr Val Ala Val Arg 195 200 205 Ser Pro Ser Met Asn Val Ala Leu Tyr Val Gly He Ala Val Gly Val 210 215 220 Val Ala Ala Leu He He He Gly He He He Tyr Cys Cys Cys Cys 225 230 235 240 Arg Gly Lys Asp Asp Asn Thr Glu Asp Lys Glu Asp Ala Arg Pro Asn 245 250 255 Arg Glu Ala Tyr Glu Glu Pro Pro Glu Gin Leu Arg Glu Leu Ser Arg 260 265 270 Glu Arg Glu Glu Glu Asp Asp Tyr Arg Gin Glu Glu Gin Arg Ser Thr 275 280 285 Gly Arg Glu Ser Pro Asp His Leu Asp Gin 290 295 The position of the first in-frame stop codon predicts a polypeptide chain, which has a M r of 33276. Based on a hydrophilicity plot constructed from the amino acid sequence, the molecule appears to have three portions: an extracellular region of 213 amino acids (which by sequence alignment of conserved residues appears to contain two immunoglobulin-like domains) , a highly hydrophobic transmembrane domain of 24-27 amino acids, and a highly polar intracellular C-terminal tail. This general structure is suggestive of the molecule being involved in signal transduction. The cDNA sequence starting at base pair 113 from the 5' end of clone 11, to base pair 1070 of clone 11, which encodes the 298 amino acid protein is as follows (SEQ ID NO: 23) : ATGGTGGGGA AGATGTGGCC TGTGTTGTGG ACACTCTGTG CAGTCAGGGT GACCGTCGAT GCCATCTCTG TGGAAACTCC GCAGGACGTT CTTCGGGCTT CGCAGGGAAA GAGTGTCACC CTGCCCTGCA CCTACCACAC TTCCACCTCC AGTCGAGAGG GACTTATTCA ATGGGATAAG CTCCTCCTCA CTCATACGGA AAGGGTGGTC ATCTGGCCGT TTTCAAACAA AAACTACATC CATGGTGAGC TTTATAAGAA TCGCGTCAGC ATATCCAACA ATGCTGAGCA GTCCGATGCC TCCATCACCA TTGATCAGCT GACCATGGCT GACAACGGCA CCTACGAGTG TTCTGTCTCG CTGATGTCAG ACCTGGAGGG CAACACCAAG TCACGTGTCC GCCTGTTGGT CCTCGTGCCA CCCTCCAAAC CAGAATGCGG CATCGAGGGA GAGACCATAA TTGGGAACAA CATCCAGCTG ACCTGCCAAT CAAAGGAGGG CTCACCAACC CCTCAGTACA GCTGGAAGAG GTACAACATC CTGAATCAGG AGCAGCCCCT GGCCCAGCCA GCCTCAGGTC AGCCTGTCTC CCTGAAGAAT ATCTCCACAG ACACATCGGG TTACTACATC TGTACCTCCA GCAATGAGGA GGGGACGCAG TTCTGCAACA TCACGGTGGC CGTCAGATCT CCCTCCATGA ACGTGGCCCT GTATGTGGGC ATCGCGGTGG GCGTGGTTGC AGCCCTCATT ATCATTGGCA TCATCATCTA CTGCTGCTGC TGCCGAGGGA AGGACGACAA CACTGAAGAC AAGGAGGATG CAAGGCCGAA CCGGGAAGCC TATGAGGAGC CACCAGAGCA GCTAAGAGAA CTTTCCAGAG AGAGGGAGGA GGAGGATGAC TACAGGCAAG AAGAGCAGAG GAGCACTGGG CGTGAATCCC CGGACCACCT CGACCAGTGA Comparison with available DNA and protein databases revealed that the protein consisting of the amino acid sequence supra (SEQ ID NO: 22) was novel. However, analysis of available expressed, sequence tag (EST) databases revealed 74% sequence similarity between part of the human A33 antigen cDNA (nucleotides 286-529) and a 249 base pair EST derived from the murine embryonal carcinoma cell line F9 (EMBL Accession No. MM88A09; DDBJ Accession No. D28657) . In the likelihood that this EST corresponded to part of the murine homologue of the human A33 antigen cDNA, sense and antisense PCR primers (17mers) were designed to hybridize to the extremities of the EST clone, as follows: Primer #1867 (F9 A33 sense) 5' GACAAAGAAATACATC (SEQ ID NO: 24) Primer #1868 (F9 A33 antisense) 5'TCTGGCTTGGAGGGTGG (SEQ ID NO: 25) These primers were used in the touchdown PCR program described above to amplify a 218 bp product from a normal adult mouse colonic crypt cDNA library. See, e.g. J. Biol. Chem. 268: 27214-27225 (1993) for details on the murine cDNA library used. Briefly the cDNA was reverse transcribed from poly(A) + enriched RNA purified from adult mouse colon crypt epithelium, and then cloned into the λgt- 11 expression vector. This product was gel-purified and DNA sequencing demonstrated that this product closely corresponded to the F9 EST: Seq 1 (SEQ ID NO: 26) Seq 2 (SEQ ID NO: 27) MM88A09 EST sequence (nucleic) mouse colon cDNA (PCR product) Seg l 5'AGTATCTAACGAGTGCTGAGGTTGTCAAATGCCTCTATCACCATCGACCAGCTGACCATGGA Seq 2 5'AGTATCTAACGA-TGCTGAG-TTGTCAAATGCCTCTATCACCATCGACCAGCTGACCATGGA Seq 1 CGACAATGGCACCTACGAGTGCTCCGGTGTCACTGATGTCGGACCAGGATGTCAACGCCAA Seq 2 CGACAATGGCACCTACGAGTGCTCCG-TGTCACTGATGTCGGACCAGGATGTCAACGCCAA Translation of the murine colonic PCR product revealed significant homology with part of the sequence of the A33 antigen (residues 64-104 of the cleaved molecule, residues 85-125 of SEQ ID NO: 22) . The alignment between the predicted human and murine protein sequences is shown below: Human (amino acids 85-125 of SEQ ID NO: 22) 85 Y K N R V S I S N N A E Q S D A S I T I D Q L T M A D N G T Y E C S V S L M S D L 125 Murine (SEQ ID NO: 28) Y E N R V R V S N D A E L S N A S I T I D O L T M D D N G T Y E C S V S L M S D Q The F9 PCR product was radiolabelled ([α 32 P]ATP and [α 32 P] CTP as before) and used as a probe in Northern analysis of multiple murine tissue RNAs (from colonic crypts, small intestinal crypts, kidney, liver, brain, spleen, thymus, lung, pancreas, testis, heart, and thigh muscle) . An intense band of approximately 2.6 kb in size was seen only in the lanes containing RNA prepared from colonic crypts and small intestinal crypts, with a very weak signal when testis and pancreas RNA were used. This close correspondence with the size of human A33 antigen mRNA, together with the alignment shown above and the restricted tissue expression, strongly suggested that the F9 clone encodes the murine homologue of the A33 antigen. In addition, these data suggest that the F9 EST contains errors and that the authentic sequence is better described by the sequence of the PCR product described herein. The F9 PCR product was then used to screen the murine colonic crypt cDNA library described supra, for full length murine A33 cDNA clones. Standard methodologies were used, and twenty clones were identified, most of which contained A33 cDNA inserts of about 2.2 kb; however, two contained longer, 4.2 kb inserts. DNA sequencing was carried out on these two longer clones, and two of the 2.2 kb clones, using standard methods. The 3' sequence of the 4.2 kb clones did not correspond to A33 antigen cDNA, and sequence similarity searching of publicly available libraries using BLAST and FASTA algorithms showed that the 3'-end corresponded to cDNA for stomach, non-muscle Ca 2+ ATP-ase. The 5' -end of all four clones was recognizable as an A33 antigen nucleotide sequence. Hence, the 4.2 kb clone comprises A33 cDNA at its 5' -end, and the stomach non- muscle Ca 2+ ATP-ase cDNA at its 3' -end. Sequencing of the 4.2 kb clones showed 2202 base pairs of A33 cDNA. The shorter clones contained 2122 base pairs of cDNA for the antigen. Translation of the longest ORF predicts a 318 amino acid protein which is not complete at the -NH 2 terminus. It shows the same basic structure as the human antigen, and is highly homologous to it. A 20 amino acid hydrophobic leader sequence (missing the initiative methionine) is seen (compared to 21 for human) , a V-set, a C2 set immunoglobulin like domain, a 24 amino acid hydrophobic transmembrane domain, and a 61 amino acid intracellular domain are presented. Further, the N- terminal region contains a consensus peptide cleavage site: ADA^LTVET (SEQ ID NO: 29) which is similar to human cleavage site: ADA"ISVET (SEQ ID NO: 30) , each of which produce a mature protein of 298 amino acids. Overall analysis shows 71% similarity between murine and human sequences in the extracellular domain, 67% in the transmembrane domain, and 54% in the intracellular domain. The murine protein shows 4 potential N-linked glycosylation sites at positions 78, 91, 179 and 202, as compared to the human sequence, which has three potential sites at 91, 179 and 202. The nucleotide and deduced amino acid sequences for the murine clone are set forth at SEQ ID NOS: 31 and 32. An alignment of the deduced amino acid sequences of human and murine sequences are set forth at figure 17. Example 17 A further set of experiments were carried out, using the protocols described supra, and the longest A33 antigen cDNA clone (clone 18) was found which also encoded A33. The nucleotide sequence of this clone is presented in SEQ ID NO: 33. This clone is slightly larger than that provided supra for clone 11, in that clone 18 is about 2.8 kilobases long, while clone 11, as indicated, is 2.6 kilobases long. In SEQ ID NO: 29, nucleotides 345 to 1302 appear to encode the amino acid sequence set forth in SEQ ID NO: 33. Example 18 As noted, supra, the A33 molecule is believed to be a glycoprotein, with N-linked glycosylation. Additional studies were carried out on relevant post-translational modifications to the antigen. As reported, supra, the cell lines SW1222, LIM 1215, and COLO 205 are all A33 positive, while SW620 and MF-SH are A33 negative. All of these cell lines were metabolically labelled with 3 H-palmitate, at 500 μCi/ml, then lysed with detergent, and the lysates were precipitated with A33 and FB5, as described supra. FB5, it will be recalled, serves as a negative control. The precipitates were then subjected to SDS-PAGE analysis, as well as autoradiofluorography. The results are shown in figures 18 and 19. In figure 18, it will be seen that A33 3 H-palmitate labelled A33 antigen, with molecular weights at reduced and non-reduced conditions which were expected. The labelled precipitates were found in all three positive cells, but neither of the negative cells. FB5 was negative in all tests. When the SDS gels were treated with 1M hydroxylamine (pH 7.5), before autoradiofluorography, staining was abolished, as figure 19 shows. This indicates that palmitate groups (acyls) , are linked via thioesters. A (Cys) 4 domain is found in the molecule, and it is proposed that the palmitate is linked thereto. The A33 antigen which has now been isolated, characterized and sequenced, can be used to diagnose cancer, colon cancer in particular which is characterized by the expression of the A33 antigen. For example, a sample suspected of containing colon cancer cells is contacted with an antibody specific for the A33 antigen or a fragment thereof, so that A33 protein/antibody complexes can be formed. If these complexes are present, a positive colon cancer diagnosis is indicated. In addition, the A33 antigen can be used to identify ligands which bind to it (binding partners) . The A33 antigen can be isolated, or recombinantly expressed, and used to screen biological sources, including tissue culture media, tissue extracts and cell lysates, for binding partners. Once a binding partner has been found, it is isolated and purified, and can be sequenced. This can be done with the use of a biosensor, in combination with affinity and other chromatographic techniques. Optionally, the A33 antigen can be tagged, to assist in immobilization of the antigen in a specific orientation onto the biosensor surface or affinity support. Identifying binding partners can be done utilizing techniques known to those skilled in the art. See, for example, Stitt et al. , Cell, Vol. 80, pp. 661-670 (1995), Nice et al. , J. Chromatography A. , Vol. 660, pp. 169-185 (1994) and Bartley et al. , Nature, Vol. 368, p. 558 (1994) ; Lachmann et al. , Proc. Natl. Acad. Sci. USA 93: 2523-2527 (1993) . Further, the cDNA encoding A33 antigen has been described herein. This cDNA, including the untranslated portions at the 5' and 3' ends, easily facilitates the production of A33 antigen double-stranded cDNA molecules from tissues and cell lines expressing the A33 antigen, and A33 antigen genomic clones from genomic DNA. To do this, the A33 cDNA is used to design complementary primers for use in the technique of RT-PCR (reverse transcriptase-PCR) , a standard procedure for the production of double-stranded cDNA molecules from mRNA templates. Further, the A33 cDNA can be used to design complementary primers for use in standard PCR reactions to amplify portions of the A33 antigen gene from genomic DNA templates. It is possible that the A33 antigen resides in a novel family of related proteins. The A33 cDNA sequence described herein can be used to design specific and degenerate oligonucleotide primers for use in low stringency PCR reactions to amplify portions of cDNA and genomic DNA molecules encoding proteins related to the A33 antigen. In addition, the A33 cDNA can be used to design specific and degenerate oligonucleotide probes for the identification of members of the A33 antigen gene family by Southern analysis of genomic DNA under low stringency conditions. These procedures utilizing A33 cDNA are standard procedures, known to those skilled in the art of molecular biology. See, for example, Molecular Cloning: A Laboratory Manual, 2nd edition, 1989 (eds. Sambrook J, Fritsch EF & Maniatis T) Cold Spring Harbor Laboratory Press, U.S.A., and Current Protocols in Molecular Biology Volumes I & II, 1989 (ed. Ausubel, FM) Greene Publishing Associates and Wiley-Interscience, U.S.A. Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of various aspects of the invention. Thus, it is to be understood that numerous modifications may be made in the illustrative embodiments and other arrangements may be devised without departing from the spirit and scope of the invention. 10 20 30 40 50 ■ ■ 1 . 1 . . . . ! ■ ■ . . I . . . . I . ■ . ■ ' • « • « > • . . . ? . . . . I t . . . ! . . . . I GTTGGGGAAGGCAGGATCTGTGGTGTGGATGCTCTGTGCAATCTGGGTCG 50 CTGCTGATGCTCTTACCGTGGAAACTACACAGGACATTCTTCGGGCTGCT 100 CGAGGAAGGAGTGTCACCCTCCCGTGCACCTACAACACCTATGTTTCAGA 150' CCGAGAGGGGTTCATTCAGTGGGATAAGCTTCTCCGAAGTCAGACGGAAA 200 GAGTGGTCACCTGGAATTTTGTGACAAAGAAATACATCTATGGGAACCGT 250 260 270 280 290 300 TATGAGAATCGAGTGAGAGTATCTAACGATGCTGAGTTGTCAAATGCCTC 300 TATCACCATCGACCAGCTGACCATGGACGACAATGGCACCTACGAGTGCT 350 CCGTGTCACTGATGTCGGACCAGGATGTCAACGCCAAGTCTCGAGTCCGC 400 CTCTTGGTCCTTGTTCCACCCTCCAAGCCAGACTGCAGCATCCAAGGGGA 450 GATGGTGATCGGGAACAACATCCAGCTGACATGCCACTCTGCAGAGGGCT 500 510 520 530 540 550 ■ . . . I . . . . I . . . . I . . . . I . . . . I . . . . I . . . . t . . . . I . . . . I . . . . I CTCCGAGCCCACAATACAGCTGGAAGAGTTACAACGCCCAGAACCAGCAG 550 CGGCCCCTCACCCAGCCAGTCTCAGGCGAGCCATTGTTGCTGAAGAACAT 600 CTCCACGGAGACAGCGGGTTACTACATCTGCACCTCCAGCAATGACGTGG 650 GGATAGAGTCCTGCAACATCACCGTGGCACCCAGACCTCCCTCCATGAAC 700 ATTGCGCTGTATGCGGGCATTGCGGGGAGTGTCTTTGTGGCCCTCATCAT 750 760 770 780 790 800 CATCGGTGTCATTGTCTACTGCTGCTGCTGCCGGGAAAAGGATGACAAAG 800 ATCAAGACAGGGAGGATGCGCGGCCGAACCGAGCAGCTTACCAAGTGCCT 850 AAAAAGGAGCAGAAAGAAATTTCCAGAGGGCGGGAAGACGAAGATGACCA 900 CAGACATGAGGATCGGTGGAGCTCGGGGCGTAGCACTCCAGACCAGCCTT 950 TCCAATGAAGGAGCCTTCTGCCCAGCGGGGAGAGGGGGGAGGTCTAGGGC 1000 1010 1020 1030 1040 1050 ■ ■ ' * ' ' • ■ • < ■ » ■ . ! . . » « I » . . . I . . . . I i . . . I . . . . I . . . . I . ■ . . I CCAGGCTCCTGCTCTGGCCACCCTTCTCCCCAGCCCCATAGTCCTGCTCC 1050 TCCCCCCAGGCATTGGTGGAGCACTTCTTTCTGTGTATCTGCCTCAGGGG 1100 CGCATCACTGGCCTGGCTACTGACGTCCTACCTGATGACCACTGAAAGGA 1150 CCCTTCCTCATTGCTAAATCTGACTCAGGGTCTGGCCTTCTCCCTAGACC 1200 AGACAGCATCCTCTGCCTCTCTTACGGCTGGCAGGGCCTCCTAGAATCTC 1250 1260 1270 1280 1290 1300 t ■ « ■ I . . . . I . . . . ϊ . . . . I . . . . I . . . . I . . . . I . . . . I t . . . I . . . . I GGCACGATGCAGGGCTGCTTCTGTTCCAAGCTCGCCATACAGGCAAGCGC 1300 CAGCTTCAGCACCAGTTTCAGAAGGTGGGAGTCTGCCCTGCCTCACCATG 1350 CCCGACACTCAGAGGAGAACCAGTGATGGGCCTGCACGCAATATTTTGTT 1400 GAATGAAGGGAAGAAATCAACGATAAGGTGTAGTTTCTGTGATTTACCCA 1 50 GCTTAATTGCGCCCCCCCCCCCCCATGCTGAGGGGCCACGGTGGCCTCCA 1500 1510 1520 1530 1540 1550 ■ . . . i . . . . t . . . . I . . . . i . . . . i . . . . i . . . . I . . . . i . . . . I . . . . I GCGT C CC CC TCTG C T C CATCT C CCAC C ATGGCGTTTCTGTTCCTGGACAC 1550 ACACCTTCTTAGGACTTCTCCAAACACAGTTCCATCTCTGCCTGTCAAGG 1600 GCCTGCCTGTCCTTAGAACTCACTAGTCTTGGATCCCCAAATCTTTCTTA 1650 ATCCTGTGACTGCTAACACACCAGGAGGCAATGAAGTCACTTTGTCCCAC 1700 ACCTAGACCTGGGCTGCATGCAAGGCCATCAGAGCTACACTTCCTGCTGT 1750 SEQ ID NO: 31 1760 1770 1780 1790 1800 GTTAGAGTAGGTGCCCTGGAGCAAGGTCTGGATCTTGGAGCCTGGCAGCC 1800 TCAACTGGGGACTTGCTCTCATGGACAGTGCTTTGCCTCCTGGGTGTGAC 1850 TTGGGACACCTGGTGACTCCACCCAAGCCCCGTGTTAGTCTGGCTAGGTG 1900 GGCAGACTGATTTACAATGAACACAGACAAAAGCTTACTTCCCTCGCACC 1950 TGCCAGCTGCCCTGCCTGCCGCAGCCTCCCCTTTCCATTACTATCCAGGA 2000 2010 2020 2030 2040 2050 ■ I , . 1 . . t i l . . . ■ I t . . . I . . . . I m i l n i l I I I I l l ■ ■ ■ ■ ! t ι . . I CTCAGGCCAGATGGGCTGCTCCAAATGTGTTTTACTACTGGATAAACCTT 2050 TCTGGATCACCAGAAAAGCAACTGTATCAATCCCTTCCCTCCTCTGATTT 2100 TATGTACACATATATTTTATATACTTGGCTAAATTCTTTGTTTCAATCAA 2150 AATGTTTCTTTATCAATAAAGTTACTGGTGGAAATTCAAAAAAAAAAAAA 2200 AA 2202 10 20 30 40 LGKAGSVVWMLCAJWVAADALT ET7QDILRAARGRSVTL 40 ( -315 PCTYNTYVSDREGF1QWDKLLRSQTERVVTWNFVT KYIY 80 GN YENRVRVSNDAE SNAS1TIDQLTMDDNGTYECSVSL 120 MSDQDVNAKSRVR LVLVPPSKPDCS1QGEMVIGNNIQLT 160 CHSAEGSPSPOYSWKSYNAQNQQRPLTQPVSGEPLLL NI 200 210 220 230 240 STETAGYYICTSSNDVGIESC ITVAPRPPSMN1ALYAG1 240 AGSVFVALJ I I GV 1 VYCCCCREKDDKDQDREDΛRPNRAAY 280 QVPKKEQKEISRGREDEDDHRHEDR SSGRSTPDDPFO. 319 SEQ ID NO: 32 NUCLEOTIDE SBUUIIWV.E, UΓ --».-.-.. .__ CTACCCC TTG'rGAGCAGTCTAGGACTTTGTACACCTGTTAAGTAGGGAGAAGGCAGGGGAGCTGGCTGGTT AAGGGGA BO AClTGAGaGAAG'J'AGGGAAGACTCCTCTTGGGACCTTTGGAGTAGG'GACACATGAGCCCAGCCCCAGCTCACCTGCCAA 160 TCCAGCTGAGaAGCTCACCTGCCAATCCAGCTGAGCCTGGGCAGAGGTGGGTGAGAAGAGGGAAAATTGCAGGGACCTCC 240 AGTTGGGCCAGGCCΛGAAGCTGCTGTAGCTTΪAACCAQΛCAGCTCAGACCTσTCTGGΛGGCTGCCAGTGACAGGTTAGG'i' 320 TTAGGGCAGAGAAGΛΛGCAAGACCΛTGGTGGGGAAGATCTGGCCTGTGTTGTGGACACTCTGTGCAGTCΛGGGTGACCCT 400 CGATGCCAΪCTCTGTGGAΛΛCTCCGCΛGGACGTΪCTTCGGGCTTCGCAGGGΛΛAGAGTGT ΛCCCTGCCCTGCACCTACC 480 ACACTTCCACC CCAGTCGAGAGGGACT ATTCAATGGGATAAGCTCCTCCTCACTCATACGGAAAGGGTGGTCArCTGG 560 CCGTTTTCΛΛACAAAAACTACATCCATGGTGAGCTTTATAAGΛΛTCGCGTCΛGCATATCCAΛCAATGCTGΛGCAGTCtCGA 640 TGCCTCCATCACCATTGAT AGCTGACCA'GGCTGACAACGGCACCTACGAGTGTTCTGTCTCGCTGATGTCAGACCTGG 720 AGGGCAACACCAAGTCACGTGTCCGCCTGTTGGTCCTCGTGCCACCCTCCAAACCAGAATGCGGCATCCΛGGGAGAG CC BOO ATAATTGGGAACAACA'CCAGCTGACCTGCCAATCAAAGGAGGGCTCACCAACCCCTCAGTACAGCTGaAAGΛGGTACAA 8β0 CATCCTGAΛ CAGGAGCAGCCCCTCGCCCAGCCAGCCTCAΠGTCAGCCTGTCTCCCTGAAΠAA ΛTCTCCACAGΛCΛCAT 960 CGGGTTACTACΛTCTGTACC CCAGCAAA'GAGGACGGGACGCAGTTCTGCAACATCΛCΒGTGGCCGΪCAGATCTCCCΪCC 1040 ATGAACGTCCCCCTGTATGTCGGCATCGCGGTGGGCGTGGTTGCAGCCC CATTATCATTGGCATCATCATCTACTGC G 3320 CTGC'J'GCCGAGGGΛAGGACGACAΛCACTCAAGACAAGGACGΛTGCAACGCCGAACKGGAAΛGCCTATGAGGΛGCCACCAG 17.00 AG ΛGCTAAGAGΛΛCTTTCCAGΛGAGAGGGΛGGAGΠAGGΛTGACTACAGGCAAGAAGAGCΛOAGΠAGCACTGGGCGTGAA 12BO TCL'CCGGACCAC CGACCAGTGΛCAGGCCAGCAGCAGAGGGCGGCGGAGGΛAGGGTTACGGGTTCATTCTCCCGCTTCC 1360 TGGCCTCCCTTCTCCTTTCTAAGCCCTGTTCTCCTGTCCCTCCATCCKAGACATTGATGCGGΛCATTTCTTCCCCAGTGT 1 40 CAGCTGTGGGCAACATGGCTGGCCTGGTAAGGGGGTCCCTGTGCTGATCCTGCTGACCTCAC'RGTCCTGTGAAGTAACCC 1520 CTCCTUCCTGTGACACCTGGTGCGGCCCTGGCCR.TCΛCTCAAGACCΛGGCTGCAGCCTCCACTTCCCTCGTAGTΪGGCΛG 1600 GAGCTCCTGGAAGCACAGCGCTGAGCATGC;GGCGCTCCCACTCAGAACTCTCCAGGGACGCGATGCCAGCCTTGGGGGGT 16B0 GGGGGCTGTCCTGCTCACCTGTGTGCCCΛGCACCTGGΛGGGGCACCΛGGTGGACCCTTTGCACTCCACΛCATCTTTCTTG 176 AAΪGAATGAAAGΛΛTAAGTGAGTΛTGCTTGGGCCCTGCATTGGCCTGGCCTCCΛGCTCCCACTCCCTTT CAACCTCACT 1840 TCCCGYAGCTGCCAGTATGTTCCAAACCCTCCTGGGAAGGCCACCTCCCACTCCTCCTGCACAGCCCCTGGGGAGCTTTT 1920 GCCCACΛCACTTTCCATC CTGCCTCTCΛΛTATCGTΛCCTGTCCCTCCAGGCCCATCTCAAATΓACAΛGGATTTCTCTAΛ 2000 CCCTATCCTAATTGTCCACATACGTGGAAACAATCCTGTA'ACTCTGTCCCACGTCCAATCATGGGCCACAAGGCACAGTC 2080 TTCTGAGCGAGTGCTCTCACTGTATTAGAGCGCCAGCTCCTTGGGGCAGGGCCTGGGCCTCATGGCTTTTGCTTTCCCTN 2160 ΛAΣCCCTAC ΛGCTGAEΣCCCΛTCCTAGTGGGCACTTAAGCTTAATTGCGGΛΛACTΣCTTTGΛTTΣΣTTGTGCCT'X'CCCT 2240 TCTCTGGTC CCTTGAGATGΛTCGTAGACACΛGGGATGATTCCCACCCAAACCCACGTATTCAT CAGTGAGTTAAΛCΛC 2320 GAATTGATT AAAGTGAACACACACAAGGGAGCTTGCTTCCAGATGGTCTCAGRI'CTTGTGTCCTGGTAATTCCTCTCCA S400 GGCCAGAATAA'I'TGGCATGTCTCCTCAAΓCCΛCΛTGGGGTTCCTGGTTGTTCC GCATCCCGATΛCCTCAGCCCTGGCCC 24B0 TGCCCAGCCCATT GGGCTCTGGT TTCTGGTGGGGCTGTCCTGCTGCCCTCCCACΛGCCTCCTTCTGTTTGTCGAGCΛT 2560 TTCaTCTACTCTTGAGAGCTCAGGCAGCGTTAGGGCTGCTTAQGTCTCATGGACCACTGGCTGGTCTCACCCAACTGCAG 2640 TTTAGTAT GCTATCTTTTCrGGATGATCAGAAAAATAATTCCATAAATCa'ATTGTCTACTTGCGATTTTTTAAAAAATG 2720 TATΛTTTTTATATATΛTTGTTAAA'ΓCCTTTGCTTCATTCCAAATGCTTTCAGTAATΛΛTAAAATTGTGGGTGGAAAAAAΛ 2 β 00 AAA 2003 SEQ ID NO : 33

Claims: Claims 1. Isolated protein containing molecule which is found in and on the surface of colon cells and colon cancer cells, wherein said isolated protein containing molecule has a molecular weight of about 40-45 kD as determined by SDS gel electrophoresis under non-reducing conditions and about 49-50 kD as determined by SDS gel electrophoresis under reducing conditions. 2. The isolated glycosylation containing molecule of claim 1, wherein said molecule binds to monoclonal antibody A33. 3. The isolated protein containing molecule of Claim 1, wherein said molecule is recombinant. 4. Isolated protein selected from the group consisting of: the protein consisting of the amino acid sequence of SEQ ID NO: 22, and the protein consisting of amino acids 22-319 of SEQ ID NO: 22. 5. The isolated protein containing molecule of Claim 4, wherein cys43 and cysll7 of SEQ ID NO: 22 are linked by a disulfide bond. 6. Isolated peptide which binds to monoclonal antibody A33 and consists of a linear array of amino acids of SEQ ID NO: 22. 7. The isolated peptide of Claim 6, wherein said peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11. 8. Isolated nucleic acid molecule encoding A33 protein. 9. The isolated nucleic acid molecule of claim 8, wherein said molecule has the nucleotide sequence set forth in SEQ ID NO: 23. 10. The isolated nucleic acid molecule of claim 8, wherein said A33 protein has the amino acid sequence set forth in SEQ ID NO: 22 or an amino acid sequence consisting of amino acids 22-314 of SEQ ID NO: 22. 11. Expression vector comprising the isolated nucleic acid molecule of claim 8 operably linked to a promoter. 12. A host cell transformed or transfected with the nucleic acid molecule of claim 8. 13. A host cell transformed or transfected with the expression vector of claim 11. 14. Antibody specific for a protein containing molecule which is found in and on the surface of colon cells and colon cancer cells, wherein said antibody is not A33, and wherein said molecule has a molecular weight of about 40-45 kD as determined by SDS gel electrophoresis under non-reducing conditions and about 49-55 kD as determined by SDS-PAGE under reducing conditions. 15. A method of diagnosing colon cancer characterized by the presence of A33 antigen in and on the surface of colon cancer cells, comprising: (a) contacting sample suspected of containing said colon cancer cells with an antibody specific for the protein containing molecule of Claim 1, or a peptide fragment thereof, such that protein/antibody complexes are formed; and (b) determining whether said complexes are present, the presence of said complexes indicating a positive colon cancer diagnosis. 16. A method of obtaining a ligand which binds to A33 antigen, comprising: (a) isolating or expressing a molecule which contains an amino acid sequence corresponding to a linear array of amino acids of SEQ ID NO: 22; (b) screening a biological source with said molecule; (c) isolating ligand which binds to said molecule from said biological source. 17. The method of Claim 16 wherein said molecule has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 22. 18. A method of obtaining a nucleic acid molecule which encodes A33 antigen comprising: (a) developing primers complementary to the sequence set forth in SEQ ID NO: 29; and (b) performing reverse transcriptase polymerase chain reaction utilizing said primers to obtain A33 antigen double stranded cDNA from a biological source expressing the A33 antigen. 19. A method of obtaining A33 antigen gene fragments comprising: (a) developing primers complementary to the sequence set forth in SEQ. ID. NO. 29; and (b) performing polymerase chain reaction utilizing said primers to amplify A33 antigen gene fragments from an A33 antigen genomic DNA template. 20. A method of identifying proteins related to the A33 antigen comprising: (a) developing specific and degenerate oligonucleotide primers complementary to the sequence set forth in SEQ. ID. NO. 29; and (b) performing low stringency polymerase chain reaction utilizing said primers to amplify portions of cDNA and genomic DNA which encode proteins related to the A33 antigen. 21. A method of identifying proteins related to the A33 antigen comprising: (a) developing specific and degenerate oligonucleotide primers complementary to the sequence set forth in SEQ. ID. NO. 29; and (b) performing Southern analysis of genomic DNA under low stringency conditions utilizing said primers to obtain proteins related to the A33 antigen.

Inventors: BURGESS ANTONY, CATIMEL BRUNO, HEATH JOAN, JI HUNG, JOHNSTON CAMERON, MORITZ R L, NICE EDOUARD, OLD LLOYD J, RITTER GERD, SIMPSON RICHARD J, WELT SYDNEY, WHITE SARA, BURGESS, ANTONY, CATIMEL, BRUNO, HEATH, JOAN, JI, HUNG, JOHNSTON, CAMERON, MORITZ, R., L., NICE, EDOUARD, OLD, LLOYD, J., RITTER, GERD, SIMPSON, RICHARD, J., WELT, SYDNEY, WHITE, SARA
Applicants: BURGESS ANTONY, CATIMEL BRUNO, HEATH JOAN, JI HUNG, JOHNSTON CAMERON, LUDWIG INST CANCER RES, MORITZ R L, NICE EDOUARD, OLD LLOYD J, RITTER GERD, SIMPSON RICHARD J, WELT SYDNEY, WHITE SARA, BURGESS, ANTONY, CATIMEL, BRUNO, HEATH, JOAN, JI, HUNG, JOHNSTON, CAMERON, LUDWIG INSTITUTE FOR CANCER RESEARCH, MORITZ, R., L., NICE, EDOUARD, OLD, LLOYD, J., RITTER, GERD, SIMPSON, RICHARD, J., WELT, SYDNEY, WHITE, SARA
Application year: 1996
Main classification: C07K1
IPC codes: C07K14, C07K16